Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: No evidence for the role of the common FABP2 A54T gene polymorphism

Acta Neurologica Scandinavica

Volumn 115, Issue 2, 2007, Pages 90-96

  Wanby, P ^a,b   Nilsson, I ^b   Brudin, L ^a,b   Nyhammar, I ^b   Gustafsson, I ^b   Carlsson, M ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Asymmetric dimethylarginine; Carotid stenosis; Fatty acid binding protein 2 gene; Genetics; Nitric oxide; Polymorphism

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 2; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD LEVEL; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

AGED; ARGININE; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; CASE-CONTROL STUDIES; FATTY ACID-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 33845865529     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00764.x     Document Type: Article

References (29)

1. HIGASHI Y, OSHIMA T, SASAKI N et al. Relationship between insulin resistance and endothelium dependent vascular relaxation in patients with essential hypertension. Hypertension 1997;29:280-5.
2. MIYAZAKI H, MATSUOKA H, COOKE JP. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 1999;99:1141-6.
3. VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADA S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20:S60- 2.
4. WANBY P, TEERLINK T, BRUDIN L, BRATTSTRÖM L, NILSSON I, PALMQVIST P, CARLSSON M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006;185:271-7.
5. VALKONEN VP, PÄIVÄ H, SALONEN JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
6. KIELSTEIN JT, BOGER RH, BODE-BOGER SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
7. USUI M, MATSUOKA H, MIYAZAKI H, UEDA S, OKUDA S, IMAIZUMI T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-30.
8. PETTERSSON A, HEDNER T, MILSOM I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998;77:808-13.
9. HYSON D, RUTLEDGE JC, BERGLUND L. Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep 2003;5:437-44.
10. RYU JE, HOWARD G, CRAVEN TE, BOND G, HAGAMAN AP, CROUSE JR III. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 1992;23:823-8.
11. HEGELE RA, HARRIS SB, HANLEY AJG, SADIKIAN S, CONNELLY PW, ZINMAN B. Genetic variation of intestinal fatty acid-binding protein associated with variation in body mass in aboriginal Canadians. J Clin Endocrinol Metab 1996;81:4334-7.
12. ÅGREN JJ, VALVE R, VIDGREN H, LAAKSO M, UUSITUPA M. Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene. Arterioscler Thromb Vasc Biol 1998;18:1606-10.
13. ZHANG F, LÜCKE C, BAIER LJ, SACCHETTINI JC, HAMILTON JA. Solution structure of human intestinal fatty acid binding protein: Implications for ligand entry and exit. J Biomol NMR 1997;9:213-28.
14. BAIER LJ, SACCHETTINI JC, KNOWLER WC et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995;95:1281-7.
15. CARLSSON M, ORHO-MELANDER M, HEDENBRO J, ALMGREN P, GROOP LC. The T 54 allele of the fatty acid-binding protein 2 is associated with a parental history of stroke. J Clin Endocrinol Metab 2000;85:2801-4.
16. WANBY P, PALMQUIST P, RYDEN I, BRATTSTROM L, CARLSSON M. The FABP2 gene polymorphism in cerebrovascular disease. Acta Neurol Scand 2004;110:355-60.
17. WANBY P, PALMQUIST P, BRUDIN L, CARLSSON M. Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. Vasc Med 2005;10:103-8.
18. BÖGER RH, BODE-BÖGER SM, THIELE W, JUNKER W, ALEXANDER K, FRÖ LICH JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
19. SCHULZE F, WESEMANN R, SCHWEDHELM E et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-83.
20. BLUTH EI, WETZNER SM, STAVROS AT, AUFRICHTIG D, MARISH KW, BAKER JD. Carotid duplex sonography: a multicenter recommendation for standardized imaging and Doppler criteria. RadioGraphics 1988;8:487-506, Figure 22.
21. ARMITAGE P, BERRY G, MATTHEWS JNS. Statistical methods in medical research, 4th edn. London: Blackwell Scientific Publications, 2002; 677 pp.
22. CANANI LH, CAPP C, NG DP et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 2005;54:3326-30.
23. AXELSEN M, SMITH U, ERIKSSON JW, TASKINEN MR, JANSSON PA. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 1999;131:27-31.
24. BOQUIST S, RUOTOLO G, TANG R et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999;100:723-8.
25. LUNDMAN P, ERIKSSON MJ, STUHLINGER M, COOKE JP, HAMSTEN A, TORNVALL P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111-6.
26. FARD A, TUCK CH, DONIS JA et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:2039-44.
27. VALKONEN VP, LAAKSO J, PAIVA H et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl 2003;4:19-22.
28. LU TM, DING YA, LEU HB, YIN WH, SHEU WH, CHU KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61.
29. MARTENS-LOBENHOER J, BODE-BÖGER SM. Measurement of asymmetric dimethylarginine (ADMA) in human plasma: from liquid chromatography estimation to liquid chromatography-mass spectrometry quantification. Eur J Clin Pharmacol 2006;62(Suppl. 13):61-8.